21
Sep
2010
Okairos, AG: Series B $20.8M
Posted in I - Series B, Q - 3Q10, R - INTERNATIONAL, X - HIV, X - Hepatitis C, X - Influenza, X - Malaria, X - Vaccines
Okairos (Switzerland) a clinical-stage biopharmaceutical company developing T-cell vaccines against infectious diseases such as malaria, HIV, hepatitis C and influenza, closed a $20.8M Series B financing. Participants include Versant Ventures, Boehringer Ingelheim Venture Fund, BioMedPartners, Life Science Partners and Novartis Venture Fund.
05
Oct
2009
Amyris Biotechnologies, Inc.: Series C $24.8M
Posted in I - Series C, Q - 3Q09, R - WEST, X - Biofuel, X - Malaria, XX - CA
Amyris Biotechnologies (Emeryville, CA) a development-stage biofuels company focused on metabolic pathway transformations of plant-based feedstocks into different isoprenoids, closed a $24.8M Series C financing. Participants include Khosla Ventures, Kleiner Perkins Caufield & Byers, DAG Ventures and TPGBiotech.
OnBioVC PARTNERS
-
